News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Advaxis, Inc. Approved To Receive Cash Allocation Through New Jersey Technology Business Tax Certificate Transfer (NOL) Program



12/12/2013 8:31:12 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

PRINCETON, N.J.--(BUSINESS WIRE)--Advaxis, Inc., (NASDAQ:ADXS), a leader in developing the next generation of cancer immunotherapies, announced that it is one of 54 companies approved to share the $60 million allocation through the New Jersey Technology Business Tax Certificate Transfer (NOL) Program in Fiscal Year 2014. Each of the 54 selected companies is expected to receive approximately $1.1 million which is a 21% increase from last year.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES